

AMENDMENTS TO THE CLAIMS

The following is a detailed listing of all claims that are, or were, pending in the present application.

1. (Original) An isolated human CT120 protein polypeptide comprising the amino acid sequence of SEQ ID NO: 2, or its conservative variant polypeptide, active fragment or active derivative.
2. (Original) The polypeptide of claim 1, wherein said polypeptide is selected from the following group:
 - (a) a polypeptide having the amino acid sequence of SEQ ID NO: 2;
 - (b) a polypeptide derived from the polypeptide (a) with one or more substitution, deletion or insertion in the amino acid residues of polypeptide (a), which has the function of promoting the growth of NIH/3T3 cell.
3. (Withdrawn) An isolated polynucleotide comprising a nucleic acid sequence selected from the following group:
 - (a) polynucleotides encoding the polypeptide according to claims 1 and 2;
 - (b) polynucleotides which are complementary to polynucleotides (a).
4. (Withdrawn) The polynucleotide of claim 3, wherein the polypeptide encoded by said polynucleotide has the amino acid sequence of SEQ ID NO: 2, or said polynucleotide has a sequence selected from the following group: the sequence in encoding region of position 91-861 of SEQ ID NO: 1 or the full length sequence position 1-2145 of SEQ ID NO: 1.
5. (Withdrawn) A vector comprising the polynucleotide of claim 3.

6. (Withdrawn) A genetic engineered host cell selected from the following group:
 - (a) host cell transformed or transduced by the vector of claim 5;
 - (b) host cell transformed or transdues by the polynucleotide of claim 3.
7. (Withdrawn) A method for producing a polypeptide comprising:
 - (a) culturing the host cell of claim 6 under the conditions suitable for the expression of protein;
 - (b) isolating the polypeptides having the activity of tumor-related protein CT120 from the culture.
8. (Withdrawn) An antibody specifically binding with the human CT120 of claim 1.
9. (Withdrawn) A method for detecting the carcinomatous change or susceptibility for carcinomatous change in pneumonocytes, comprising the steps of:

detecting whether there is any CT120 transcript in the pneumonocyte sample, the presence of CT120 transcript indicating that said pneumonocyte undergoes carcinomatous change or has the susceptibility for carcinomatous change; or

detecting whether there is CT120 protein in the pneumonocyte sample, the presence of CT120 protein indicating that said pneumonocyte undergoes carcinomatous change or has the susceptibility for carcinomatous change.
10. (Withdrawn) A kit for detecting pulmonary cancer, which comprises (1) primers which specifically amplify human CT120 gene, or (2) antibody specifically binding with CT120 protein.